| Comparison in purity and antitumor effect of brand and generic paclitaxel against human ovarian cancer cells by an in vitro experimental model. | |
| | |
MedLine Citation:
|
PMID: 20818963 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
CONTEXT: The purity and the therapeutic effectiveness of the generic paclitaxel have not yet been examined and compared to the original brand form. OBJECTIVE: This study aimed to compare the in vitro purity and biological effects of original brand form (Taxol) and a generic drug of paclitaxel. MATERIALS AND METHODS: Purity was determined by high-performance liquid chromatography analysis, cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay, cell proliferation by clonogenic assay, morphology by Liu's staining, and cell cycle distribution by DNA histogram. RESULTS: Taxol and generic paclitaxel shared similar high-performance liquid chromatography profiles with a major peak at the same retention time and ultraviolet spectrum. Generic paclitaxel inhibited the cell viability to an extent greater than Taxol. By assessing the IC(50), generic paclitaxel also exhibited a greater inhibitory activity on clonogenicity of human ovarian adenocarcinoma SKOV-3 cells. Although both generic paclitaxel and Taxol arrested SKOV-3 and ES-2 cells at G2/M phase with concurrent development of hypoploid and polyploid cells, Taxol treatment exhibited markedly less extent of these changes. Observation of cellular morphology revealed a greater amount of mitotic catastrophe-like and apoptotic cells in generic paclitaxel-treated cells than Taxol-treated cells. DISCUSSION AND CONCLUSION: The results suggest that generic paclitaxel may possess a greater cell death inducing capacity and clonogenicity inhibitory activity against ovarian cancer cells than the original brand Taxol of the same purity. We conclude that this experimental model for assessing the difference between generic and brand name drugs might be considered as a reference while determining their interchangeability and could be easily established in a hospital-based laboratory. |
| | |
Authors:
|
Kung-Liahng Wang; Yuh-Cheng Yang; Jerry Cheng-Yen Lai; Tung-Hu Tsai; Chin-Ping Lin; Yu-Tse Wu; Yu-Yawn Chen; Shen-Chuan Wang; Yu-Jen Chen |
Related Documents
:
|
20373763 - Gut metabolites of anthocyanins, gallic acid, 3-o-methylgallic acid, and 2,4,6-trihydro... 20399283 - Evaluation of phenolphthalein, diazepam and quinacrine dihydrochloride in the in vitro ... 17179233 - Nonmalignant t cells stimulate growth of t-cell lymphoma cells in the presence of bacte... |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Drug development and industrial pharmacy Volume: 36 ISSN: 1520-5762 ISO Abbreviation: Drug Dev Ind Pharm Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-07 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7802620 Medline TA: Drug Dev Ind Pharm Country: England |
Other Details:
|
Languages: eng Pagination: 1253-8 Citation Subset: IM |
Affiliation:
|
Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan, PR China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Synthesis, self-assembly, and characterization of PEG-coated iron oxide nanoparticles as potential M...
Next Document: Surface responses and desirability functions to determine optimal granulation domains.